Commercial Perspectives: Pegylated Interferons - Leading the Way in HCV Therapy? - Datamonitor Premium Research Reports

Report title: Commercial Perspectives: Pegylated Interferons - Leading the Way in HCV Therapy?

from Datamonitor Premium Research Reports
102 page (31193 word) report published Apr 17, 2003

Price $3,800.00 available for immediate download

Report Overview

Search Inside

About Datamonitor Premium Research R...

...Low diagnosis rates across the seven major markets mean that Schering-Plough and Roche will need to continue their internet-based disease awareness campaigns if the full potential of pegylated interferons is to be tapped. Efficacy and side-effect profile similarities between PEG-Intron and Pegasys mean that marketing and promotional effectiveness will be key to product success. ...

Industry(ies):

Healthcare, Infectious Diseases

Free Sample:

Click Here to Download

Format:

PDF

Enter the keyword(s) which you would like to search for within this document and click "Search"

Datamonitor is a premium business information company specializing in industry analysis. Datamonitor's industry research addresses complex strategic issues by providing unbiased expert analysis and in-depth forecasts across the Automotive, Consumer, Energy, Financial Services, Healthcare & Technology sectors.

Price: $3,800.00

Free Sample

Questions about
this research?

Send page to a friend

Return to
Alacra Company Snapshot

Get FREE Research

Can't Decide?

Purchasing premium research sight unseen can be intimidating. We want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.